Reversible Valproate-Induced Subacute Encephalopathy Associated With a MT-ATP8 Variant in the Mitochondrial Genome(54 visite) De Michele G, Sorrentino P, Nesti C, Rubegni A, Ruggiero L, Peluso S, Antenora A, Quarantelli M, Filla A, De Michele G, Santorelli FM
Front Neurol (ISSN: 1664-2295linking, 1664-2295print), 2018 Aug 30; 9(AUG): 728-728.
Tipo di articolo: Journal Article,
Impact factor: 3.508, Impact factor a 5 anni: 4.297
Parole chiave: Mt-Atp8, Ammonia, Metabolic Encephalopathy, Mitochondria, Valproate, Cytochrome C Oxidase, Lactic Acid, Succinate Dehydrogenase, Valproic Acid, Aged, Article, Brain Cortex Atrophy, Brain Disease, Case Report, Clinical Article, Deterioration, Disease Severity, Dna Sequence, Drowsiness, Drug Dose Titration, Drug Withdrawal, Electroencephalogram, Electron Transport, Enzyme Activity, Epilepsy, Female, Follow Up, Gaze Paralysis, Gene Deletion, Gene Mutation, Genetic Association, Genetic Variability, Human, Human Tissue, Lactate Blood Level, Leukoencephalopathy, Limb Weakness, Mitochondrial Genome, Mt Atp8 Gene, Muscle Biopsy, Muscle Strength, Neurologic Examination, Nuclear Magnetic Resonance Spectroscopy, Single Nucleotide Polymorphism, Treatment Duration, Walking Difficulty,
Affiliazioni:
*** IBB - CNR *** Department of Neurosciences and Reproductive and Odontostomatological Sciences, Universita degli Studi di Napoli Federico II, Napoli, Italy. Molecular Medicine, IRCCS Fondazione Stella Maris, Pisa, Italy. Institute of Biostructure and Bioimaging, National Research Council, Naples, Italy.
Riferimenti:
Galimberti, C.A., Diegoli, M., Sartori, I., Uggetti, C., Brega, A., Tartara, A., Brain pseudo-atrophy and mental regression on valproate and a mitochondrial DNA mutation (2006) Neurology, 67, pp. 1715-171
Nesti, C., Meschini, M.C., Meunier, B., Sacchini, M., Doccini, S., Romano, A., Additive effect of nuclear and mitochondrial mutations in a patient with mitochondrial encephalomyopathy (2015) Hum Mol Genet, 24, pp. 3248-3256
Tomson, T., Battino, D., Perucca, E., Valproic acid after five decades of use in epilepsy: time to reconsider the indications of a time-honoured drug (2016) Lancet Neurol, 15, pp. 210-218
Verrotti, A., Trotta, D., Morgese, G., Chiarelli, F., Valproate-induced hyperammonemic encephalopathy (2002) Metab Brain Dis, 17, pp. 367-373
Gerstner, T., Buesing, D., Longin, E., Bendl, C., Wenzel, D., Scheid, B., Valproic acid induced encephalopathy-19 new cases in Germany from 1994 to 2003-a side effect associated to VPA-therapy not only in young children (2006) Seizure, 15, pp. 443-448
Lewis, C., Deshpande, A., Tesar, G.E., Dale, R., Valproate-induced hyperammonemic encephalopathy: a brief review (2012) Curr Med Res Opin, 28, pp. 1039-1042
Baganz, I., Dross, P.E., Valproic acid-induced hyperammoncmic encephalopathy: MR appearance (1994) Am J Neuroradiol, 15, pp. 1779-1781
Ziyeh, S., Thiel, T., Spreer, J., Klisch, J., Schumacher, M., Valproate-induced encephalopathy: assessment with MR imaging and 1H MR spectroscopy (2002) Epilepsia, 43, pp. 1101-1105
Guerrini, R., Belmonte, A., Canapicchi, R., Casalini, C., Perucca, E., Reversible pseudoatrophy of the brain and mental deterioration associated with valproate treatment (1998) Epilepsia, 39, pp. 27-32
Mock, C.M., Schwetschenau, K.H., Levocarnitine for valproic-acid-induced hyperammonemic encephalopathy (2012) Am J Health Syst Pharm, 69, pp. 35-39
Senior, A.E., Nadanaciva, S., Weber, J., The molecular mechanism of ATP synthesis by F1F0-ATP synthase (2002) Biochim Biophys Acta, 1553, pp. 188-211
Dautant, A., Meier, T., Hahn, A., Tribouillard-Tanvier, D., di Rago, J.P., Kucharczyk, R., ATP Synthase Diseases of Mitochondrial Genetic Origin (2018) Front Physiol, 9, p. 329
Hroudova, J., Fisar, Z., Activities of respiratory chain complexes and citrate synthase influenced by pharmacologically different antidepressants and mood stabilizers (2010) Neuro Endocrinol Lett, 31, pp. 336-342
Luis, P.B., Ruiter, J.P., Aires, C.C., Soveral, G., de Almeida, I.T., Duran, M., Valproic acid metabolites inhibit dihydrolipoyl dehydrogenase activity leading to impaired 2-oxoglutarate-driven oxidative phosphorylation (2007) Biochim Biophys Acta, 1767, pp. 1126-1133
Lam, C.W., Lau, C.H., Williams, J.C., Chan, Y.W., Wong, L.J., Mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes (MELAS) triggered by valproate therapy (1997) Eur J Pediatr, 156, pp. 562-564
Chaudhry, N., Patidar, Y., Puri, V., Mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes unveiled by valproate (2013) J Pediatr Neurosci, 8, pp. 135-137
Bianco, A., Martínez-Romero, I., Bisceglia, L., D'Agruma, L., Favia, P., Ruiz-Pesini, E., Mitochondrial DNA copy number differentiates the Leber's hereditary optic neuropathy affected individuals from the unaffected mutation carriers (2016) Brain, 139, pp. 1-3
Ciccarelli M, Sorriento D, Coscioni E, Iaccarino G, Santulli G * Adrenergic Receptors(13 visite) Endocrinol Of The Heart In Health And Dis (ISSN: 9780-1280311249780128031117), 2016; N/D: 285-315. Impact Factor:0 DettagliEsporta in BibTeXEsporta in EndNote
47 Records (42 escludendo Abstract e Conferenze). Impact factor totale: 180.771 (162.246 escludendo Abstract e Conferenze). Impact factor a 5 anni totale: 185.63 (165.512 escludendo Abstract e Conferenze).
ibb.cnr.it